RT Journal Article
SR Electronic
T1 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21252736
DO 10.1101/2021.03.09.21252736
A1 ,
A1 Horby, Peter W
A1 Estcourt, Lise
A1 Peto, Leon
A1 Emberson, Jonathan R
A1 Staplin, Natalie
A1 Spata, Enti
A1 Pessoa-Amorim, Guilherme
A1 Campbell, Mark
A1 Roddick, Alistair
A1 Brunskill, Nigel E
A1 George, Tina
A1 Zehnder, Daniel
A1 Tiberi, Simon
A1 Aung, Ni Ni
A1 Uriel, Alison
A1 Widdrington, John
A1 Koshy, George
A1 Brown, Thomas
A1 Scott, Steven
A1 Baillie, J Kenneth
A1 Buch, Maya H
A1 Chappell, Lucy C
A1 Day, Jeremy N
A1 Faust, Saul N
A1 Jaki, Thomas
A1 Jeffery, Katie
A1 Juszczak, Edmund
A1 Lim, Wei Shen
A1 Montgomery, Alan
A1 Mumford, Andrew
A1 Rowan, Kathryn
A1 Thwaites, Guy
A1 Mafham, Marion
A1 Roberts, David
A1 Haynes, Richard
A1 Landray, Martin J
YR 2021
UL http://medrxiv.org/content/early/2021/03/10/2021.03.09.21252736.abstract
AB Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety and efficacy of convalescent plasma in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) several possible treatments are being compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated to receive either usual care plus high titre convalescent plasma or usual care alone. The primary outcome was 28-day mortality.Findings Between 28 May 2020 and 15 January 2021, 5795 patients were randomly allocated to receive convalescent plasma and 5763 to usual care alone. There was no significant difference in 28-day mortality between the two groups: 1398 (24%) of 5795 patients allocated convalescent plasma and 1408 (24%) of 5763 patients allocated usual care died within 28 days (rate ratio [RR] 1·00; 95% confidence interval [CI] 0·93 to 1·07; p=0·93). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (66% vs. 67%; rate ratio 0·98; 95% CI 0·94-1·03, p=0·50). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of progression to invasive mechanical ventilation or death (28% vs. 29%; rate ratio 0·99; 95% CI 0·93-1·05, p=0·79).Interpretation Among patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant refs: MC_PC_19056; COV19-RECPLA).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).Clinical Protocols https://www.recoverytrial.net Funding StatementUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant refs: MC_PC_19056; COV19-RECPLA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial is conducted in accordance with the principles of the International Conference on Harmonisation-Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, the trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. https://www.ndph.ox.ac.uk/data-access